Acral melanocytic lesions in the United States: Prevalence, awareness, and dermoscopic patterns in skin-of-color and non-Hispanic white patients - 18/04/17
Abstract |
Background |
Acral lentiginous melanoma has increased mortality compared with other melanoma subtypes and disproportionately affects ethnic minorities. Acral melanocytic lesions have not been well studied in diverse populations of the United States.
Objective |
We sought to assess the prevalence, awareness, and dermoscopic patterns of acral melanocytic lesions in skin-of-color and non-Hispanic white patients.
Methods |
We prospectively examined the palms and soles of 1052 patients presenting to dermatology clinics in New York, NY, and Miami, FL, from October 2013 to April 2015.
Results |
Acral melanocytic lesions were observed in 36% of our cohort. Skin-of-color patients were more likely to have acral melanocytic lesions than non-Hispanic white patients (P < .01). Acral melanocytic lesions correlated with increased mole counts, particularly on non-Hispanic white patients. The majority of lesions demonstrated benign dermoscopic patterns. We observed 2 lesions with the parallel ridge pattern in our cohort, both found to be atypical nevi on biopsy specimen. Patients often lacked awareness of the presence of their lesions.
Limitations |
Interobserver variability in assessing dermoscopic patterns is a limitation.
Conclusions |
Melanocytic lesions of the palms and soles are common, particularly in a cohort of multiple ethnicities from the United States. Dermoscopy of acral lesions is an important clinical tool for diagnosis and management of these lesions.
Le texte complet de cet article est disponible en PDF.Key words : acquired acral nevi, acral lentiginous melanoma, acral melanocytic lesions, acral pigmented lesions, dermoscopy, skin of color
Plan
Supported by a research grant (12-01910) from the Skin Cancer Foundation (Dr Stein). |
|
Disclosure: Dr Stein was supported by the Irwin I. Lubowe Fellowship in Dermatology. Dr Grichnik has served as a consultant for Amgen, Castle Biosciences, Caliber Imaging & Diagnostics Inc, and Novartis and is a major shareholder of DigitalDerm Inc. Ms Madankumar; Drs Gumaste, Martires, Schaffer, Choudhary, Falto-Aizpurua, Patel, Sanchez, Yin, Chan, Sanchez, Polsky, and Kanavy; Ms Arora; Ms Kallis; and Ms Damanpour have no conflicts of interest to declare. |
|
Presented in part at the May 2014 Society for Investigative Dermatology Annual Meeting, Albuquerque, NM. |
Vol 74 - N° 4
P. 724 - avril 2016 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?